New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|February 9, 2015
The Mechanism of Action and Toxicity Profile of Duvelisib (IPI-145)
Author(s)Ian W. Flinn, MD, PhD
Ian W. Flinn, MD, PhD, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.
Advertisement
Clinical Pearls
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.
- Duvelisib inhibits both delta and gamma isoform.
- The hope is that the molecule targets both the tumor cell as well as the microenvironment.
- The toxicity profile of duvelisib is still being studied.
- To date, the molecule appears to have a similar toxicity profile of other PI3K inhibitors.
Advertisement
Related to this article
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5